scispace - formally typeset
Book ChapterDOI

Pharmacological actions of cannabinoids.

Roger G. Pertwee
- 01 Jan 2005 - 
- Vol. 168, Iss: 168, pp 1-51
Reads0
Chats0
TLDR
More information is beginning to emerge about the pharmacological actions of the non-psychoactive plant cannabinoid, cannabidiol, as well as acting on CB1 and CB2 receptors, and there is convincing evidence that anandamide can activate transient receptor potential vanilloid type 1 (TRPV1) receptors.
Abstract
Mammalian tissues express at least two types of cannabinoid receptor, CB1 and CB2, both G protein coupled. CB1 receptors are expressed predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors

read more

Citations
More filters
Journal ArticleDOI

Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands

TL;DR: The results reveal that a set of novel cannabinioid receptor ligands potently inhibit T- type calcium channels and show analgesic effects in vivo, and suggest possible novel means of mediating pain relief through mixed T-type/cannabinoid receptor ligANDs.
Journal ArticleDOI

Central functional response to the novel peptide cannabinoid, hemopressin.

TL;DR: It is demonstrated that hemopressin activates distinct neuronal substrates within the brain, focused mainly on the feeding-related circuits of the mediobasal hypothalamus and in nociceptive regions of the periaqueductal grey (PAG) and dorsal raphe (DR).
Journal ArticleDOI

Effects of Cannabis sativa extract on haloperidol-induced catalepsy and oxidative stress in the mice

TL;DR: It is concluded that cannabis improves catalepsy induced by haloperidol though the effect is not maintained on repeated cannabis administration, and alters the oxidative status of the brain in favor of reducing lipid peroxidation, but reduces brain glucose, which would impair brain energetics.
Journal ArticleDOI

The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.

TL;DR: The current understanding of the endocannabinoid system in human pathologies is summarized and a review of the results from preclinical studies examining its function in cardiovascular disease is provided, with a particular emphasis on possible CB2-targeted therapeutic interventions to alleviate atherosclerosis.
Journal ArticleDOI

Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease.

TL;DR: Cannabidiol, through multi-target mechanisms, represents a valid therapeutic tool for the management of epilepsy, Alzheimer's disease, multiple sclerosis and Parkinson’s disease.
References
More filters
Journal ArticleDOI

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

TL;DR: This issue of Pharmacological Reviews includes a new venture in the collaboration between the International Union of Pharmacology (IUPHAR) and the American Society for Pharmacology and Experimental Therapeutics (ASPET), in that a new classification of voltage-gated ion channels is outlined.
Journal ArticleDOI

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

TL;DR: In this article, an arachidonylethanthanolamide (anandamide) was identified in a screen for endogenous ligands for the cannabinoid receptor and its structure was determined by mass spectrometry and nuclear magnetic resonance spectroscopy and confirmed by synthesis.
Journal ArticleDOI

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

TL;DR: The cloning and expression of a complementary DNA that encodes a G protein-coupled receptor that is involved in cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana are suggested.
Journal ArticleDOI

International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

TL;DR: It is considered premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, because pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging and other kinds of supporting evidence are still lacking.
Related Papers (5)
Trending Questions (1)
How do you stimulate cb1 receptors?

These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state.